Clinical Trials Directory

Trials / Completed

CompletedNCT00689949

Validation of Urinary Biomarkers of Folate Status

Determination of the Suitability of Urinary Total P-aminobenzoylglutamate (p-ABG)and Formiminoglutamate (FIGLU) as a Markers for Folate Status

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
53 (actual)
Sponsor
Ludwig-Maximilians - University of Munich · Academic / Other
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The major objective of the proposed study is to demonstrate the suitability of new markers for folate status in humans, which avoid blood sampling, as required for the established marker RBC folate concentration, but can be obtained from spot urine samples. For this reason urine and blood will be collected from volunteers, twice at baseline and in a subgroup after 6 and 12 weeks of intake of a folic acid supplement Specific hypotheses to be tested: Correlation study: * The 24 h urinary excretion of total p-ABG, as extrapolated via urinary creatinine concentration from the total p-ABG concentration in a spot sample is significantly correlated to RBC and plasma folate levels in the studied subjects * The 24 h urinary excretion of FIGLU, as extrapolated via urinary creatinine concentration form the FIGLU concentration in a spot sample is significantly correlated to RBC and plasma folate levels in the studied subjects Intervention study: Changes in folate status (RBC folate) after supplementary intake of folate result in increased urinary excretion of total p-ABG and FIGLU in subjects identified with a low folate status and in subjects identified with a high folate status among the study participants of the correlation study

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTfolic acid0.4 mg of folic acid per day

Timeline

Start date
2008-06-01
Primary completion
2008-10-01
Completion
2012-12-01
First posted
2008-06-04
Last updated
2012-12-24

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT00689949. Inclusion in this directory is not an endorsement.